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ABSTRACT
First line drug treatment of follicular lymphoma (FL) patients is followed by a 
highly variable disease-free time before relapse in about one third of patients. No 
molecular marker is able to predict efficiently the risk of relapse. We investigated 
the expression profile of microRNAs (miRNAs) by microarrays and of the tumor 
microenvironment by immunohistochemistry in 26 FLs and 12 reactive lymph nodes 
(rLN) as reference. Twenty-nine miRNAs were differentially expressed in FLs compared 
to rLNs and some of them discriminated grade 1 from 3a FLs. Both FLs and rLNs 
displayed molecular heterogeneity. FLs grouped into two clusters mostly driven by 
the tumor T-cell content. Among 21 drug-treated FL patients with an average follow-
up of 13.5 years, eight cases relapsed. Twenty-six miRNAs discriminated between 
relapsed and non-relapsed FLs. Ten miRNAs also correlated with Foxp3+ cells number. 
Notably, Foxp3+ cells were significantly less in relapsed patients and lower Foxp3+ cell 
number associated with shorter time-to-relapse. Foxp3+ cells did not co-expressed 
follicular helper T-cell markers and were therefore classified as regulatory T cells 
rather than follicular regulatory T-cells. These findings introduce new knowledge 
about the relationship between miRNA alterations and infiltrating immune cells and 
show that Foxp3+ cells might be predictive of disease relapse.
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INTRODUCTION
Follicular lymphoma (FL) is a low-grade B cell 
lymphoma usually characterized by long life expectancy 
and heterogeneous outcome. About one third of FL patients 
alternate periods of disease remission with recurrent 
relapses. Some FLs undergo histologic transformation to 
a high-grade neoplasm, a transition associated with a more 
aggressive clinical course and poor survival [1]. 
The current evaluation of the risk of relapse/
resistance to multiagent chemotherapy of FL is based on 
clinical parameters summarized in the Follicular Lymphoma 
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International Prognostic Index (FLIPI) while no consistent 
biological marker has been identified that predicts the 
survival or the risk of relapse after drug treatments [2]. The 
majority of candidate biomarkers studied in FL patients 
focused on morphologic features, cytogenetic abnormalities, 
molecular aberrations, somatic mutations and altered 
protein expression [3–7]. Although the new discovered 
somatic mutations are promising markers of prognosis in 
FL, to date no single hallmark or single driver mutation can 
be considered predictive of relapse. 
Gene expression studies have revealed that both 
survival and progression-free disease are significantly 
associated with non-neoplastic immune cell gene signatures 
[8, 9]. According to gene expression signatures, FLs split into 
two groups, i.e. T-cell-rich and dendritic cell-/macrophage-
rich [10–14]. In FL, T-cells number, functionality and 
distribution may impact patient prognosis. PD1+ cells 
associated with shorter time to relapse of FLs [13]. High 
number of Foxp3+ cells predicted improved survival of FL 
patients [10]. However, the association of Foxp3+ cells with 
FL outcome was questioned in other studies [2, 13].
MiRNAs play critical regulatory roles in the immune 
system and are necessary for proper lineage decision [15]. 
MiRNA biogenesis is under tight temporal and spatial control 
and dysregulation is associated with many human diseases 
[16, 17]. A direct role of miRNAs in lymphomagenesis was 
demonstrated by knock-out miRNA mouse models with a 
direct impact on B-cell lymphoma/leukemia development 
[18]. In particular, miR-155, miR-150, miR-21, cluster 
miR-17-92 and miR-34a have pivotal role in the control of 
master regulator transcription factors essential in the B-cell 
biology [19]. MiR-16 expression discriminated FLs with 
and without BCL2 translocation [20]. MiRNA signatures in 
FLs were obtained from both the comparison with reactive 
lymph nodes (rLN) or from cells isolated from FL and rLNs 
[21–24]. Despite the potential relevance of miRNAs in FL 
biology, the association between the expression level of 
deregulated miRNAs and clinical parameters of FL patients 
has not been conclusively demonstrated yet. 
The limited success of approaches applied so 
far for the identification of  prognostic markers for FL 
patients has prompted us to consider the possible role 
of miRNA signatures. Since several miRNAs pointed to 
a role of immune cells, we have investigated the tumor 
microenvironment by means of immunohistochemistry. 
We have then investigated the possible association of 
markers typical of different immune cells with miRNA 
profiles and the clinical outcome of FL patients.
RESULTS
Increasing alterations of miRNAs expression 
from low to high grade FL 
We performed miRNAs expression analysis by 
microarrays in 26 FLs and 12 reactive lymph nodes (rLN) 
as reference. In Figure 1, the heat map summarizes the 
differences in miRNA expression between FLs and rLNs 
at 10% FDR (false discovery rate), fold change >1.5. FLs 
clustered separately from rLNs except three cases. Both 
FLs and rLNs appeared heterogeneous and split apart into 
two groups. Seventeen miRNAs resulted upregulated and 
12 downregulated in FL in comparison to rLNs (Figure 
1). MiR-16 family four miRNAs, miR-15a, miR-15b, 
miR-16 and miR-195 were correlated to each other and 
upregulated in most of FLs. 
FLs distributed regardless of grade as compared 
to rLNs. However, when FLs of grade 1, 2 and 3a were 
separately compared with rLNs, FL grade 1 showed the 
upregulation of miR-21, miR-9* and miR-155 and the 
downregulation of miR-340; FL grade 3a showed the 
upregulation of five miRNAs and the downregulation 
of five miRNAs (Figure 2A and 2B). In FL grade 3, 
the increase of miR-219, miR-28 and miR-34a and the 
decrease of miR-329, miR-320, miR-519e* and miR-516-
5p expression added to those altered in FL grade 1 (Figure 
2C). FL grade 2 showed no significant differences in 
comparison to rLNs as well as the direct comparison of 
FL of different grade.
Expression of several miRNAs was validated by 
quantitative RT-PCR in rLN, FL1, FL3a and all FLs 
(Supplementary Figure 1). MiR-28 (P = 0.05), miR-9 
(P = 0.002), miR-9* (P = 0.0001), miR-21 (P = 0.0007) 
and miR-195 (P = 0.05) were confirmed to be upregulated 
in FLs as compared to rLN. Mir-219 was not differentially 
expressed in FLs and rLN (P > 0.1). Downregulation of 
miR-320 (P = 0.002), miR-340 (P = 0.001) and let-7i 
(P = 0.05) in FLs was confirmed.  
Ratio between expression of 5p and 3p forms of 
miR-9 and miR-21 is different in FLs compared 
to rLNs
We investigated whether the alteration of miRNA 
expression shown by FLs could imply coordinated 
changes of 5p/3p ratios. For most of miRNAs, no 
difference of 5p/3p relationships between FLs and rLNs 
could be observed whereas we observed a change of miR-
9-2/miR-9* and miR-21/miR-21* in FLs with respect to 
rLNs (Figure 3A and 3B). No change of ratio was found 
for  miR-9-1/miR-9* and miR-9-3/miR-9*.
T-cells influence the pattern of miRNAs 
expressed in FLs
FL microenvironment is characterized by the 
presence of a significant number of T-cells, up to 50% 
of the total cells [25]. To evaluate whether the T-cell 
component affected the pattern of miRNA expressed in 
FLs, we compared miRNA expression profiles of FLs with 
those of two CD4+ and two CD8+ T-cell samples (Figure 
4A and 4B). As expected, FLs and pure T-cells clustered 
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separately and a large number of miRNA discriminated 
the two categories of samples. Differentially expressed 
miRNAs split in 3 main clusters. FLs in turn clustered 
into two groups independently from the FL grade. The 
same heatmap showing the complete list of differentially 
expressed miRNAs between FLs and T-cells is reported in 
Supplementary Figure 2. 
We firstly focused on miRNA cluster 1, which 
included miRNAs expressed at high level in both FLs 
and T-cells. To evaluate the possible influence of T-cells 
on miRNA expression profile of FLs, we measured the 
level of CD3E, CD3D and CD3G mRNA in FLs by qRT-
PCR (Figure 4A). The two clusters of FLs were termed 
FL-LT (low T) and FL-HT (high T) (Figure 4A, miRNAs 
in cluster 1 listed on the right). Accordingly, by plotting 
the average expression level of the three CD3 chains upon 
each FL we found that the FL-HT group had a significantly 
higher level of CD3 than FL-LT (P < 0.01) (Figure 4A).
We searched for specific miRNAs representing a 
possible T-cell signature in FLs. To this aim, we correlated 
the levels of each miRNA with the average level of CD3 
mRNA. MiR-342 (P = 0.01) and miR-370 (P = 0.0002) 
showed clear correlation with CD3 level (Figure 4C). 
Similarly, correlations were obtained between the mRNA 
level of CD28, another marker of T-cells, and miR-342 
(P = 0.0004) or miR-370 (P = 0.0009) (Figure 4C).
Remaining miRNAs differentially expressed 
between FLs and T-cells discriminated cases belonging 
to FL-HT and FL-LT. Cluster 2 included miRNAs 
overexpressed in FL-HT group while cluster 3 included 
miRNAs overexpressed in FL-LT group (Figure 4A). 
To gain functional information about the cellular 
Figure 1: Profile of miRNAs differentially expressed between FLs and rLNs. The heat map describes the expression of 36 
spots, corresponding to 29 single miRNAs, differentially expressed among 38 samples: 26 follicular lymphoma (FLs) and 12 reactive 
lymph nodes (rLNs) (FDR 10%). FL-1, FL-2, FL-3a, FL-3b are FL of grade 1, 2, 3a and 3b, respectively. Red, higher expression (log2, 
+4); green, lower expression (log2, -4). The tables report the list of 17 miRNAs upregulated in FLs and of 12 miRNAs downregulated in 
FL in comparison to rLNs and the corresponding Q values. White circles: upregulated in Rohele et al. [23]. Black circles: downregulated 
in Rohele et al. [23]. White triangles: upregulated in isolated FL cells in Wang et al. [24]. R, relapsed; NR, not relapsed; n.a. not available.
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process potentially regulated by differentially expressed 
miRNAs, we performed pathway enrichment analysis 
using experimentally validated gene targets of miRNAs 
(Supplementary Tables 2 and 3). Target genes regulated 
by cluster 2 were mostly involved in T-cell and B-cell 
development, in cell cycle, and were under Treg 
(regulatory T-cells), NF-kB and MYC influence. Main 
pathways associated with cluster 3 included monocytes, 
macrophages, dendritic cells, Treg, follicular helper T-cells 
and B-cell receptor activation, as well as NF-kB, caspase 
and epithelial-mesenchymal transition.
Immuno-architectural pattern and total number 
of Foxp3+ and PD1+ cells but not CD68+ cells 
discriminate FLs from rLNs
Number and pattern distribution of regulatory 
T-cells (Foxp3+), suppressive and exhausted cytotoxic 
T-cells (PD1+), and macrophages (CD68+) were shown to 
variate considerably among FLs [10, 11, 13]. To evaluate 
these immune effector subsets in our FL series, we 
assessed Foxp3+, PD1+ and CD68+ cells by automated IHC 
in 24 FLs and in 11 rLNs as reference (Figure 5, Figure 6, 
Supplementary Figures 3–5). 
The immuno-architectural structure of immune 
follicles was taken in account. Only intrafollicular/
interfollicular Foxp3+ cells ratio was significantly higher 
in all FLs compared to rLNs (P = 0.03) (Figure 5A). 
Intrafollicular Foxp3+ cells were not significantly different 
in FLs of diverse grade with respect to rLNs (Figure 5B). 
Interfollicular Foxp3+ cells in FL grade 3 were significantly 
lower in number than in rLNs (P = 0.03) (Figure 5C). 
Intrafollicular/interfollicular Foxp3+ cells ratio was not 
significantly different between FL grade 1, 2 and 3 and 
rLNs (Figure 5D). 
Interfollicular PD1+ cells were higher in FLs 
compared to rLNs (P = 0.02) and the intrafollicular/
interfollicular ratio was higher in rLNs (P = 0.008) 
(Figure 6A). Intrafollicular PD1+ cells were not 
significantly different in FL grade 1, 2 and 3 compared 
to rLNs (Figure 6B), while interfollicular PD1+ cells were 
more evident in FL grade 1 (P = 0.0001) and FL grade 3 
(P = 0.02) (Figure 6C). The intrafollicular/interfollicular 
PD1+ cells ratio was lower in grade 1 and grade 3 FL with 
respect to rLNs (P = 0.03 and P = 0.006, respectively) 
(Figure 6D).
In a minority of tumors, high density of 
macrophages infiltrating the tumor correlated with lower 
Figure 2: Profile of miRNAs differentially expressed between FL grade 1 or 3a and rLNs. FL-1 and FL-3a are follicular 
lymphoma (FL) of grade 1 and 3a, respectively. Red, higher expression (log2, +4); green, lower expression (log2, –4). (A) The heat maps 
describe the expression of 14 spots, corresponding to 11 single miRNAs, differentially expressed in 20 samples: eight FLs grade 1 and 
12 reactive lymph nodes (rLNs) (FDR 10%). (B) The heat maps describe the expression of 5 spots, corresponding to 4 single miRNAs, 
differentially expressed among 20 samples: eight FLs grade 3a and 12 rLNs (FDR 10%). (C) The table reports the list of 11 miRNAs 
upregulated (up) or downregulated (down) in FL grade 1 and 3a in comparison to rLNs. 
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Figure 3: Combined expression levels and trend of 5p and 3p variants of miR-9-2 and miR-21 in FLs and rLNs. (A) 
Graph reports the expression level of miR-9-2 and miR-9* (from microarray data) in 21 follicular lymphomas (FLs) cases having clinical 
information (black circles) and in 12 reactive lymph nodes (rLNs) (empty circles). (B) Graph reports the expression level of miR-21 and 
miR-21* (from microarray data) in 21 FLs cases having clinical information (black circles) and in 12 rLNs (empty circles). Bottom graphs 
report slope and 95% confidence interval of the trend lines passing through the symbols of the two series represented in top graphs.
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survival [2, 11, 26]. As expected according to morphology, 
we observed less intrafollicular and more interfollicular 
CD68+ cells in FL compared with rLNs, but both findings 
were not statistically significant. Total CD68+ cells did 
not change in the two sets (Supplementary Figure 3). A 
summary of Foxp3+, PD1+ and CD68+ total cell in FLs and 
rLNs, together with CD3 mRNA levels in FLs, is reported 
in Supplementary Figure 4. No correlation was found 
between Foxp3+ cells and CD3 mRNA levels in FLs.
Foxp3+CXCL13+ and Foxp3+PD1+ cells are rare 
in FL and rLN
In order to characterize the T-cells infiltrating 
the FL, we investigated the regulatory follicular T 
cells (TFR) cells, a subset of suppressive T-cells which 
together with follicular helper T-cells (TFH) cells control 
the GC reaction [27–29]. TFR cells share phenotypic 
characteristics with TFH cells and conventional Foxp3+ 
Figure 4: Profile of miRNAs differentially expressed among FLs, CD4+ T-cells and CD8+ T-cells. FL-HT, follicular 
lymphoma (FL) with high T-cell level. FL-LT, with low T-cell level. (A) The heat map describes the expression levels of miRNAs 
differentially expressed among 30 samples: 26 FLs, two CD4+ and two CD8+ T-cell samples (FDR 1%). FL-1, FL-2, FL-3a, FL-3b are FLs 
of grade 1, 2, 3a and 3b, respectively. Red, higher expression (log2, +4); green, lower expression (log2, -4). On the right of the heat map a 
partial list of miRNA differentially expressed among the three sets of samples, which are expressed at higher level in T-cells than in FLs 
(miRNA cluster 1). On the top of the heat map is the average mRNA expression level of three CD3 chains gamma, delta and epsilon for 
each of the 26 FL samples. Expression data were obtained by qRT-PCR. (B) Array tree of 30 samples based on the expression levels of 
miRNAs differentially expressed. (C) Correlation between the expression levels of miR-342 or miR-370 (from microrray analysis) and the 
expression level (log2) of CD3 and CD28 mRNAs by qRT-PCR in 26 FLs samples. P was calculated by Spearman’s correlation.
Oncotarget19967www.oncotarget.com
cells and express significant amounts of the prototypic 
TFH genes Cxcr5, CXCL13, Icos, Bcl6 and PD1 [28, 30]. 
We assessed slides double stained for Foxp3-CXCL13 
as well as Foxp3-PD1 by IHC in FL and rLN samples. 
Foxp3+CXCL13+ cells were very rarely observed in FL 
and rLN (Supplementary Figure 6A and 6B). Foxp3+PD1+ 
cells were rare or less than 5% of Foxp3+ cells in the 
neoplastic GC (Supplementary Figure 6C and 6D). A 
significant number of Foxp3+PD1+ cells was observed 
in case T20 (Supplementary Figure 6D). Single-positive 
CXCL13 or PD1 cells represented a variable fraction 
mostly in the GC cells (Supplementary Figures 6A–6D).
CD8+ cells are reduced in FL in comparison to rLN
CD8+ cells are mainly involved in target cell killing 
and their increased infiltration was correlated to a better 
FL prognosis [31]. We assessed abundance and distribution 
of CD8+ cells in FL and rLN (Supplementary Figure 6E 
and 6F). The frequency of intratumoral CD8+ cells ranged 
from 1.5% to 56.1% of cells in FL patients (Supplementary 
Figure 7A). CD8+ cells were mostly interfollicular and in 
general less than 2% were intrafollicular. In FL cases T15 
and T44, CD8+ cells infiltrated significantly also the GC 
compartment (Supplementary Figure 6E). 
Figure 5: Intrafollicular, interfollicular and total Foxp3+ cell count in FLs and rLNs. White circles, follicular lymphomas 
(FLs); black circles, reactive lymph nodes (rLNs);  black line, median. Intra, inter and total are intrafollicular, interfollicular and 
intrafollicular plus interfollicular Foxp3+ cells, respectively. Number of Foxp3+ cells in each FL and rLN case was the average number 
of cells in two consecutive slides. The average number of positive cells was normalized on the whole number of nuclei present in a slide. 
P values were calculated by t-test. (A) Foxp3+ cell counts in intrafollicular, interfollicular, total and interfollicular/intrafollicular ratio in 
FLs and rLN. (B) Intrafollicular Foxp3+ cell counts in FL grades and LNs. (C) Interfollicular Foxp3+ cell counts in FL grades and LNs. 
(D) Interfollicular/intrafollicular ratio Foxp3+ cell counts in FL grades and LNs.
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CD8+ cell counts were lower in FL compared to rLN 
(P = 0.05) (Supplementary Figure 7A). Moreover, CD8+ 
cell counts were not significantly different in relapsed and 
not relapsed FL. CD8+ cells correlated positively with 
PD1+ cells and CD68+ cells in FL (either P < 0.0001) but 
not in rLN (Supplementary Figure 7B and 7C). 
We calculated the CD8+/Foxp3+ cell ratio in FL and 
rLN samples. This ratio did not discriminate FL from rLN 
and relapsed from not relapsed FLs.  
Twenty-six miRNAs are differentially expressed 
between relapsed and not relapsed FLs
Twelve patients did not relapse after treatment, 
while nine FL patients relapsed. We compared the 
expression levels of miRNAs in relapsed and non-
relapsed FLs. According to microarray data, 17 miRNAs 
were significantly upregulated and nine miRNAs were 
significantly downregulated in relapsed FLs (P < 0.05) 
(Table 1).
The expression of ten miRNAs correlates with 
Foxp3+ cell counts in FLs and rLNs
We searched for miRNAs correlating with Foxp3+, 
CD68+ or PD1+ cells in FLs and rLNs. Ten miRNAs 
showed correlation with Foxp3+ cells in FLs: directly, 
mir-325, miR-376b, mir-450-2 and miR-515-1 (P < 0.05) 
(Supplementary Figure 8A), and inversely miR-144, 
miR-302b, miR-325, mir-431, miR-432 and miR-490 
Figure 6: Intrafollicular, interfollicular and total PD1+ cell counts in FLs and rLNs. White circles, follicular lymphomas 
(FLs); black circles, reactive lymph nodes (rLNs); black line, median. Intra, inter and total are intrafollicular, interfollicular and 
intrafollicular plus interfollicular PD1+ cells, respectively. Number of PD1+ cells in each FL and rLN case was the average number of 
cells in two consecutive slides. The average number of positive cells was normalized on the whole number of nuclei present in a slide. P 
values were calculated by t-test. (A) PD1+ cell counts in intrafollicular, interfollicular, PD1+ total and interfollicular/intrafollicular ratio 
in FLs and rLNs. (B) Intrafollicular PD1+cell counts in FL grades and rLNs. (C) Interfollicular PD1+cell counts in FL grades and rLNs. 
(D) Interfollicular/intrafollicular ratio PD1+ cell counts in FL grades and rLNs.
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(P < 0.05) (Supplementary Figure 8B). For eight of the 
ten miRNAs correlating with Foxp3+ cells in FLs, the 
relationship between miRNA level and Foxp3+ cells was 
not significantly different in FLs and rLNs. In contrast, 
the inverse correlation of miR-144 with Foxp3+ cells was 
lost in rLNs, while the direct correlation of miR-302b in 
FLs turned into inverse correlation in rLNs (P = 0.04) 
(Supplementary Figure 8A and 8B).
No correlation was observed between total CD68+ or 
PD1+ cells and miRNAs level in FLs and rLNs.
Foxp3+ cell counts are lower in relapsed FL 
Clinico-pathological characteristics of FL patients 
were described in Table 2. Foxp3+, PD1+ and CD68+ 
cells were compared in relapsed and non-relapsed FLs. 
PD1+ and CD68+ cells were not significantly different 
between relapsed and non-relapsed FLs (P > 0.1). Instead, 
intrafollicular, interfollicular and total Foxp3+ cells were 
less represented in relapsed than in non-relapsed FLs 
(P = 0.01, P = 0.01, P = 0.003, respectively) (Figure 7A).
The comparison between miRNAs involved in FL 
relapse and miRNAs correlating with Foxp3+ cell counts 
in FLs was summarized by Venn diagram (Figure 7B). 
Five miRNAs intertwined the two pools. Mir-450-2 was 
upregulated in relapsed FLs and correlated positively with 
Foxp3+ cells. MiR-144 and mir-431 were upregulated 
in relapsed FLs and correlated inversely with Foxp3+ 
cells. MiR-376b was upregulated in not relapsed FLs and 
correlated directly with Foxp3+ cells. Finally, MiR-325 was 
upregulated in not relapsed FL and correlated inversely with 
Foxp3+ cells.
 Foxp3+ cell counts associate with shorter time to 
relapse
PD1+ and CD68+ cells did not associate with time 
to relapse in FLs. Regarding Foxp3+ cells, FLs were 
subdivided in two categories according to the Foxp3+ cells, 
higher and lower than the median. FLs with lower Foxp3+ 
cells associated with a shorter time to relapse (P = 0.05) 
(Figure 8), with a median time to relapse of 2000 days.
DISCUSSION
The miRNA network supervises the cell proteome 
during lymphopoiesis and turned out essential in 
lymphomagenesis [32–34]. Although the importance of 
miRNA functions in the regulation of cellular processes 
is clear, both miRNAs deregulation and its possible use 
as a biomarker in FLs have been only partially addressed. 
The tumor microenvironment provides supportive 
signaling for the proliferation of FL cells, as well as 
protection against attack from the immune system [12, 
35, 36]. Several results have drawn attention to the host 
immune response in FLs [12]. FLs harbor up to 50% of 
T-cells [25]. Altered ratios between B-cells and other 
immune cells in FLs compared to rLNs would drive 
evident modifications of the level of molecules (i.e. mRNA 
and miRNAs) shared with lymphoma cells. Accordingly, 
two different gene expression signatures, which correlated 
with different outcomes, were identified in FLs [8]. A 
group included long surviving FLs expressing T-cell-
derived genes; another group included FLs with worse 
prognosis and enriched of genes typical of dendritic cells 
and macrophages. 
The molecular heterogeneity observed in our FLs 
and rLNs series by miRNA profiling (Figure 1) was clear 
in previous studies reporting the comparison of miRNA 
expression profiles in FLs and rLNs [21, 37, 38] but not in 
another study [23]. To test the hypothesis that the miRNA 
profile of FLs implies an immune signature, we compared 
FLs and pure T-cells, more abundant among the immune 
cells infiltrating the FLs. Similarly to what observed by 
gene expression data, FLs split into two clusters. The FL-
HT cluster included miRNAs expressed at higher level 
in both FLs and T-cells (miRNA cluster 1). The higher 
level of CD3 mRNA in this group of FLs point to T-cells 
as main driver of this signature. These findings suggest 
that the clonal expansion of abnormal B-cells alters the 
immune response microenvironment, leaving a trace in the 
miRNA profile of FLs.
Being expressed at higher level in FL than in pure 
T-cells, both the cluster 2 miRNAs (overexpressed in FL-
HT group) and the cluster 3 miRNAs (overexpressed in 
FL-LT group) could not be ascribed to a T-cell signature. 
Instead, miRNAs of the cluster 2 (mainly members of the 
tricistrons miR-199b/100-125b) were found expressed 
at higher level in NK cells, some myeloid cell lineages 
and in CD4+ rather than CD8+ T-cells [39]. Tumor cells 
suppress the antitumor immune response from helper 
T-cells, cytotoxic T lymphocytes, and macrophages by 
various mechanisms [40]. Consequently, the feature 
signatures of the two FL groups might recapitulate how 
the malignant B-cells alter the function of T-cells in the FL 
microenvironment in order to escape immunosurveillance. 
Pathway enrichment analysis on target genes of 
miRNA cluster 2 showed a significant enrichment in 
pathways related to B-cells and T-cells activation and 
development as well as to cell cycle and control by MYC. 
For miRNA cluster 3, we found enrichment in pathways 
connected with mononocytes, macrophages, T helper and 
B-cell activation, as well as NF-kB, UV response and 
apoptosis. These results are reminiscent of the identification 
of two groups of FLs with different prognosis based on the 
gene expression signatures [8]. 
The two members of the cluster 1 miR-342 and miR-
370 strongly correlated with two representative markers 
of T-cells CD3 and CD28. A connection between miR-342 
and T-cells infiltrating the lymphomas was previously 
reported. Mir-342 was reported to be higher in T-cells than 
B-cells and in naive and Th17 CD4+ than in CD8+ T-cells 
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[41, 42]. Moreover, MiR-342-3p expression associated the 
CD3+ T-cells in ALK- anaplastic large cell lymphoma [43]. 
Since B-cell lymphomas may display an increased CD4+/
CD8+ T-cells ratio with respect to rLNs, it is possible that 
in FLs miR-342 represents a signature associated with 
CD4+ T-cells [35]. Abnormal number and activity of Th17 
cells has been associated to autoimmune disorders and 
inflammation [44]. In B-cell lymphomas, altered B-cells 
might skew the balance of Treg cells and Th17 cells versus 
the increase of inhibitory microenvironment [45].
Various miRNAs reported to be differentially 
expressed in FLs play regulatory roles in lymphomagenesis 
[46]. We identified a set of 27 miRNAs differentially 
expressed between FLs and rLNs. Among these, miR-9*, 
miR-16, miR-195, miR-15b and miR-374, but not miR-30-
5p, were previously found overexpressed in FL compared 
to rLNs [23]. Moreover, miR-9* and miR-155 have been 
found overexpressed also in B-cells purified from FLs 
with respect to those from rLNs [24]. Among 17 miRNAs 
upregulated in FLs, miR-29 family, miR-195, miR-15/16, 
miR-30 family, miR-146a are known to be downregulated 
Table 1: MiRNAs up-regulated or down-regulated in relapsed versus not relapsed FLs and their reported 
experimentally validated gene targets
MiRNAs upregulated in relapsed vs not relapsed FL
miRNA P value Gene targets*
miR-376c 0.0046 ACVR1C, IGF1R, GRB2, TGFBR1, TGFA
mir-450-2 0.0102 -
mir-431 0.0110 -
miR-1 0.0123 MCL1, PTEN and other 17 targets
miR-382 0.0126 BCL6, NFKB and other 22 targets
miR-9 0.0145 BCL6, ETS, PRDM1 and other 42 targets
miR-19b 0.0166 MYCN, PTEN and other 21 targets
miR-522 0.0190 SOX2, FXN
miR-181a* 0.0194 NANOG
miR-101 0.0206 MYCN, EZH2, FOS, MCL1 and other 26 targets
miR-320 0.0264 MCL1, PTEN and other 17 targets
miR-526a 0.0306 -
miR-196a 0.0328 NFKBIA,  BACH1, 6 HOX genes and other 8 targets 
miR-383 0.0475 CCND1, VEGFA and other 5 targets
miR-144 0.0492 NOTCH1, TGFB1, MTOR, PTEN and other 10 targets
miR-184 0.0500 BCL2, AKT, MYC and other 5 targets
miR-9* 0.0500 RCOR1, ITGB1, GNAI1 
MiRNAs downregulated in relapsed vs not relapsed FL
miRNA P value Gene targets*
miR-325 0.0022 -
miR-302c* 0.0072 -
mir-330 0.0132 E2F1, VEGFA, CD44 and other 4 targets
mir-376b 0.0149 -
mir-194-1 0.0180 ACVR2B, CDH2, SOCS2 and other 14 targets
mir-106b 0.0360 -
miR-31 0.0363 RHOA, PPPR2A, LATS2, SATB2, FOXP3 and other 38 targets
miR-410 0.0432 MET, MDM2
mir-491 0.0494 BCL2L1, CHD4, TAF10, MMP9, GIT1, SMAD3
*experimentally validated miRNA targets according with miRTarBase, strong evidence, reporter assay [74].
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as a consequence of MYC activity on their promoters 
[47]. Most of miRNAs upregulated and downregulated in 
FLs are equally modulated in germinal centre B-cells in 
comparison to naive B-cells (our unpublished data). 
We identified a subset of seven miRNAs which 
discriminated grade 1 from grade 3a FLs. These data 
represent the first description of an increased alteration of 
miRNAs from low to high FL grade. The direct comparison 
between FLs of different grade did not return significant 
results, possibly in consequence of the low number of cases 
and the heterogeneity previously cited. Among the miRNAs 
altered in grade 3, miR-320 downregulation could be related 
to the reported increase of its gene target MCL1, which 
strongly associated with FL onset [48, 49]. 
MiRNA biogenesis is a complex process regulated 
at multiple stages [18]. The mechanisms responsible for 
the alteration of miRNA processing are not well known, 
in particular in lymphomas. Among all miRNAs here 
examined for the proportion 5p/3p, we found that miR-
9-2/miR-9* and miR-21/miR-21* proportions changed 
in FLs with respect to rLNs. The peculiarity of miR-9 
in FL was previously noticed. In fact, particularly high 
interindividual differences of MIRN9 and MIRN9* in FL 
was observed [23]. MiR-9 was also one of the 26 miRNAs 
which showed an altered proportion between different 
miRNA forms in primary effusion lymphoma [50]. Since 
miR-9-2 gene was reported to be methylated in normal 
CD19+ B-cells [51], the lymphomagenesis could imply 
Table 2: FL patients, drug treatments, IHC markers and clinical status





T15 1 52 Low No treatment 2 2 NR
T16 1 41 Low CHOP 2 1 NR
T17 1 50 Low RT 2 1 R
T18 1 48 Intermediate DHAP 2 1 R
T19 1 47 Intermediate CHOP + DHAP 2 1 NR
T20 1 76 High FluCy 0 2 NR
T21 1 51 Intermediate APO + DHAP 1 1 NR
T22 1 47 Low CHOP 1 1 NR
T23 2 37 Intermediate CHOP + DHAP 2 2 NR
T24 2 65 High CHOP 2 1 R
T25 2 60 High CHOP + DHAP 1 1 NR
T26 2 55 Intermediate CHOP 2 1 NR
T28 2 65 High CHOP + DHAP 2 1 NR
T30 3a 70 High CHOP + RT 1 1 NR
T31 3a 64 High CLB + CHOP 0 2 R
T33 3a n.a. n.a. n.a. 2 1 n.a.
T34 3a 71 High CLB 1 1 R
T35 3a 69 High CHOP 2 1 NR
T37 3a 56 Low Surgery 2 1 R
T38 3a 47 Low CHOP 1 1 R
T39 3a 56 Intermediate APO + DHAP 2 1 NR
T40 3a 67 Low RT 2 1 R
T42 3b n.a. n.a. n.a. 1 1 n.a.
T43 3b 70 High Steroids 1 1 n.a.
T44 3b n.a. n.a. n.a. 1 1 n.a.
T45 3b 77 Intermediate CLB 0 1 NR
n.a., not available; R, relapsed; NR, not relapsed. IHC: 0, absent; 1, 1+, weak stain; 2, 2+ strong stain; CHOP: 
cyclophosphamide, adriamycin, vincristine and prednisone-based regimen; APO: adriamycin, vincristine and prednisone-
based regimen; DHAP: dexametasone, high dose-cytarabin and cisplatin-based regimen; FluCy: fludarabin and 
cyclophosphamide-based regimen; CLB: clorambucil; RT: radiotherapy. 
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Figure 7: Foxp3+ cell counts in relapsed and not relapsed FLs and Venn diagram of miRNAs upregulated in relapsed 
or not relapsed FLs and of miRNAs correlated directly or inversely with Foxp3+ cell counts. Number of Foxp3+ cells in 
each follicular lymphoma (FL) was the average of cells in two consecutive slides. The average number of positive cells was normalized on 
the whole number of nuclei present in a slide. (A) Comparison of intrafollicular, interfollicular and total Foxp3+ cells in relapsed and not 
relapsed FLs. P values were calculated by t-test. (B) Venn diagram of miRNAs upregulated in relapsed or not relapsed FLs (dark grey) and 
the intersection (intermediate grey) with miRNAs correlated directly or inversely with Foxp3+ cell counts (light grey). 
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changes of miR-9-2 methylation and of its expression. It is 
not yet demonstrated whether miR-9 alteration point to a 
etiologic field defect for FL genesis [52].
The level of specific miRNAs associated with 
clinical behaviour in our cohort of FL patients [23]. 
We could not associate miRNA expression and overall 
survival due to the low number of deaths in our series. 
Instead, we identified a set of 26 miRNA differentially 
expressed between relapsed and non-relapsed FL. None 
of the 26 miRNAs overlapped with those reported in 
the literature to be associated with FL outcome. Among 
miRNAs discriminating relapsed from non-relapsed FLs, 
several have been linked to drug resistance in lymphomas 
and other cancer types. 
Malignant B-cells can attract Tregs or suppressive 
cells, thus influencing the patterns of miRNA expressed 
in FL tissues. Foxp3+ Tregs are relevant for B-cell 
development as they control the germinal centre response 
[28]. We observed a direct correlation of four miRNAs and 
an inverse correlation of six miRNAs with total Foxp3+ 
cells in FLs. Notably, miRNAs level and PD1+ or CD68+ 
cells did not show any correlation, thus supporting the 
idea that Foxp3+ cells are those mainly involved in setting 
of miRNAs level. MiR-144 and miR-302b level, which 
correlated inversely with Foxp3+ cells in FL, lost this trend 
in rLNs. MiR-144 was shown to target BCL6 in diffuse 
large B-cell lymphoma [53]. Since relapsed FLs showed 
higher level of miR-144 and lower number of Foxp3+ cells, 
it can be hypothesized that both events might cooperate in 
supporting the proliferation of FL cells. 
In FL, Foxp3+ Treg cells might represent from less 
than 5% up to 25% of the germinal center T-cells [10, 28]. 
Treg cells might have significant clinical relevance in FL 
since they can serve as tumor-killing cells. Lower number 
of Tregs correlated with refractory disease, transformation, 
and aggressive histology of FL [10, 14, 54]. However, other 
studies failed to confirm this conclusion [55, 56]. Rather 
than Treg cells total content, the architectural distribution 
Figure 8: Time to relapse probability curves based on total Foxp3+ cell counts in FL patients. Top curve represents FL cases 
with total Foxp3+ cells higher than median. Bottom curve represents FL cases with total Foxp3+ cells lower than median.
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and pattern of Foxp3+ cells correlated with the outcome 
of patients [55]. Intrafollicular Foxp3+ cells pattern, but 
not a diffuse pattern, was found associated with poorer 
overall survival in FL patients. Our data confirmed the 
clinical relevance of both total number and pattern of 
Foxp3+ cells in FL patients. In our FL series, intrafollicular, 
interfollicular and total Foxp3+ cells were lower in relapsed 
than not relapsed FLs. Moreover, interfollicular Foxp3+ 
cells in grade 3 FLs, but not in FLs of inferior grade, were 
lower than in rLNs. Importantly, lower than median Foxp3+ 
cells associated with shorter time to relapse of FL patients. 
Taken together, our results and those reported by Farinha 
et al. [55] suggest that the immuno-architecture of the 
microenvironment around transformed B-cells impacts on 
patient outcome in terms of time to relapse and of survival 
of FL patients. 
PD1 receptor was demonstrated to suppress 
cytokines signaling in lymphoma-infiltrating T-cells [57]. 
PD1 is expressed by intratumoral CD4+ follicular helper 
T-cells and from exhausted cytotoxic T-cells [58]. A 
diffuse pattern of PD1 staining associated with a shorter 
time before transformation and inferior overall survival 
[13, 58]. At variance with these authors, according to our 
data no association was established between the pattern of 
PD1 positivity and time of relapse. 
TFH cells and TFR cells subtypes are recognized 
essential for the physiological regulation of humoral 
immunity. TFR cells are immune suppressive by limiting 
TFH cells action and GC B-cells number [28, 59, 60]. 
The specification of the two T-cell populations is driven 
by mechanisms operated by lineage-specific transcription 
factor as T-bet and BCL6 [61] and by mesenchymal stem 
cells [62].  It is believed that TFR cells arise from thymic 
regulatory T-cells. However, absence of Foxp3 expression 
in GC suppressive T-cells suggested also a possible origin 
of TFR from TFH cells [63]. TFR cells were reported to 
express significant amounts of the prototypic TFH genes 
CXCR5, CXCL13, ICOS, BCL6 and PD1 in mouse [28]. 
Foxp3+PD1+CXCL13+ TFR cells were detected in various 
mice and human settings [27–29, 64, 65]. Foxp3+PD1+ cells 
have been previously reported to be rare or absent in human 
FL, diffuse large B-cell lymphoma, Hodgkin’s disease, 
T-cell lymphoma normal tonsils and rLN [54, 66–69]. 
Small amount (1–4%) or absence of Foxp3+PD1+ cells 
were found in breast cancer tissues [70, 71], suggesting the 
possibility that the phenotype of TFR cells in lymphomas 
and cancer does not overlap those in other physiological 
contexts [62]. We observed clear staining for PD1 or 
CXCL13 in sparse cells within the neoplastic follicles of FL 
and the two signals were almost always independent from 
that of Foxp3. Only one FL cases showed a  significant 
number of double stained cells. The general rarity of TFR 
cells in FL and rLN could be suggestive of a skewed T-cell 
differentiation in sustaining the immune activation.
The recruitment of CD8+ cells into the lymph nodes 
was found protective of a disease-free survival in FL 
patients [25]. We found that CD8+ cells distributed mainly 
in interfollicular areas and were in higher number in FL than 
in rLN. In our series CD8+ cell counts did not associate with 
relapse and not relapsed status of FL patients.
In conclusion, our data reveal new miRNAs involved 
in FL in comparison with rLN. The miRNA signature in 
FL was interpreted in light of the significant infiltration 
of immune cells typical of a quote of FLs. In this regard, 
lower infiltration by Foxp3+ cells is a feature of relapsed 
FLs and also associated with shorter time to relapse. High 
levels of miR-144 and mir-431, which are upregulated 
in relapsed FL and inversely correlated with Foxp3+ cell 
number, and of miR-376b, which is upregulated in non-
relapsed FL and is directly correlated with Foxp3+ cells, 
might complement low Foxp3+ cell counts as a relapse risk 
predictor in FL patients. Multivariate analysis to assess 
combination of Foxp3+ cell number and miR-144, mir-
431, miR-376b levels as markers of FL relapse was not 
possible in this context owing to the low number of events. 
The diagnostics implication of the combined measure of 
miRNAs and Foxp3 for the risk of relapse needs to be 
confirmed on a larger FL cohort.
MATERIALS AND METHODS
Samples 
FL samples were obtained from patients accessing 
care in the Hematology section of the University of Verona 
Hospital compound (Table 1). All biopsy and blood 
samples were obtained after informed consent approved 
by Ethical Committee of AOUI of Verona (N. 1828, 
May 12, 2010 “Institution of cell and tissue collection 
for biomedical research in Onco-Hematology”). Twenty-
six patients with FL grade 1 or 2 or 3 (subdivided in 3a 
and 3b) for whom fresh/frozen pre-treatment samples 
were available were included. Twenty-one patients were 
treated with first-line chemotherapy (cyclophosphamide or 
doxorubicin or etoposide or prednisone or clorambucil), 
radiotherapy or surgery. One patient received no 
chemotherapy and another one only radiotherapy. Clinical 
follow-up was available for 21 FL patients. The average 
follow-up of patients was of 13.5 years. Time to relapse 
was defined as the time interval between complete 
remission achievement and relapse. Control samples were 
12 lymph nodes (rLNs) characterized by reactive follicular 
hyperplasia. CD4+ and CD8+ T-cells were isolated from 
blood of two healthy donors by Ficoll-Paque (Pharmacia, 
Germany) density gradient centrifugation, followed by 
positive immune affinity magnetic sorting.
Immunohistochemistry (IHC)
Number of Foxp3+, PD1+, CD68+ and CD8+ cells 
were quantified in whole-tissue sections of all samples 
using an automated scanning microscope and image 
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analysis system (S.CORE Web Based Image Analysis, 
S.CO LifeScience, Germany). Double staining for 
Foxp3-PD1 and Foxp3-CXCL13 was performed using an 
automated stainer (Leica BondMax) following standard 
protocols, as previously described [72]. Ab for Foxp3 was 
revealed by horsereadish peroxidase (nuclear). The slides 
were incubated with a second Ab then revealed by alcaline 
phosphatase (cytoplasmic). For each slide, “intrafollicular”, 
“interfollicular” and total positive cells were determined. 
The number of positive cells in each FL and rLN sample 
was the average number of cells in two consecutive slides. 
The average number of positive cells used for subsequent 
analysis was normalized on the whole number of nuclei 
present in a slide. 
Microarrays
MiRNAs labeling and hybridization were performed 
using 5 μg  total RNA, as described [73]. MiRNAs were 
named according with the old nomenclature reported in 
miRBase (www.mirbase.org). MiR-X was the 5p or 3p 
form of a miRNA and mir-X is the 5p or 3p remaining 
form of MiR-X . 
Quantitative RT-PCR
Validation of differentially expressed miRNAs and 
mRNA quantification was performed by quantitative 
RT-PCR as described in Malpeli et al. [34]. Taqman 
assays and oligonucleotide primers used are listed in 
Supplementary Table 1.
Data analysis 
Microarrays data analyses were performed as 
described in Malpeli et al. [34]. Microarray data sets 
are available on the ArrayExpress under http://www.
ebi.ac.uk/arrayexpress/experiments/E-MTAB-5844. To 
select significant differences among expressed gene or 
categories of samples, we performed using Anova tests. 
Correlation coefficients between expression of 5p and 
3p miRNA forms were calculated using Deming linear 
regression. Pathway analysis on predicted miRNA 
targets was performed by Gene Set Enrichment Analysis 
(GSEA). Experimentally validated miRNA targets (strong 
evidences) taken from MirTarBase at http://mirtarbase.
mbc.nctu.edu.tw [74] were submitted to GSEA http://
software.broadinstitute.org/gsea/msigdb/index.jsp [75, 76]. 
More significant Immunological Signatures and Hallmark 
Gene Sets were considered.  
A more extensive description of the 
methods for Nucleic acids, Quantitative RT-PCR, 
Immunohistochemistry, Microarrays and Data Analysis can 
be found in Supplementary Material. 
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